Not Yet RecruitingPhase 3Phase 4ACTRN12609000553279

Topical vs Oral agents to lower intra-ocular pressure following cataract surgery (Acetazolamide vs Brimonidine)

Among patients who undergo phacoemulsification cataract surgery, is a single dose of topical brimonidine as effective, or more effective than a single dose of oral acetazolamide to lower intra-ocular pressure, post-operatively?


Sponsor

Sir Charles Gairdner Hospital

Enrollment

56 participants

Start Date

Jul 9, 2009

Study Type

Interventional

Conditions

Summary

Tragically, one patient in this state recently suffered a fatal outcome following a severe allergic reaction to acetazolamide, a routine post-operative oral tablet used following cataract surgery to combat increases in the amount of fluid pressure within the operated eye. If not controlled, this increase in pressure can lead to damage to the optic nerve and retinal artery and vein occlusion in susceptible patients. There have been 2 similar cases of severe allergic reactions to acetazolamide reported in the medical literature. A survey of consultants in the United Kingdom found that 83% of surgeons who routinely prescribed pressure lowering medications used acetazolamide. We propose to investigate the use of brimonidine, a topical agent in a case-control study vs. oral acetazolamide in patients who have undergone phacoemulsification cataract surgery. We hypothesise that this topical agent will have a similar or superior efficacy in controlling ocular hypertension, whilst avoiding potentially serious systemic adverse effects. It is hoped that this may provide the impetus for change in clinical practice, where currently, the majority of patients are prescribed oral acetazolamide. To our knowledge, such a study comparing single dose use of these medications has not been published.


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 85 Yearss

Plain Language Summary

Simplified for easier understanding

This study compares eye drops (brimonidine) versus an oral tablet (acetazolamide) for lowering eye pressure after cataract surgery. It is open to adults aged 18-85 undergoing routine cataract surgery who do not have glaucoma.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

1) Brimonidine 0.2%, 1 eye drop immediately post operatively. 2)Oral acetazolamide, single dose 250mg tablet immediately post op.

1) Brimonidine 0.2%, 1 eye drop immediately post operatively. 2)Oral acetazolamide, single dose 250mg tablet immediately post op.


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12609000553279